Interventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review
Authors:
- Flora JungFJFlora Jung
- Keegan GuidolinKGKeegan Guidolin
- Michael Ho-Yan LeeMLMichael Ho-Yan Lee
- Kimberley Lam-Tin-CheungKLKimberley Lam-Tin-Cheung
- Grace ZhaoGZGrace Zhao
- Sachin DoshiSDSachin Doshi
- Tyler ChesneyTCTyler Chesney
- Marina EnglesakisMEMarina Englesakis
- Jelena LukovicJLJelena Lukovic
- Grainne O’kaneGOGrainne O’kane
- Fayez A. QuereshyFQFayez A. Quereshy
- Sami A. ChadiSCSami A. Chadi
Open Access
- 29 May 2021
- journal article
- review article
- Published by MDPI AG in Current Oncology
- Vol. 28 (3) , 2065-2078
Abstract
While adjuvant treatment of colon cancers that penetrate the serosa (T4) have been well-established, neoadjuvant strategies have yet to be formally evaluated. Our objective was to perform a scoping review of eligibility criteria, treatment regimens, and primary outcomes for neoadjuvant approaches to T4 colon cancer. A librarian-led, systematic search of MEDLINE, Embase, Cochrane Library, Web of Science, and CINAHL up to 11 February 2020 was performed. Primary research evaluating neoadjuvant treatment in T4 colon cancer were included. Screening and data abstraction were performed in duplicate; analyses were descriptive or thematic. A total of twenty studies were included, most of which were single-arm, single-center, and retrospective. The primary objectives of the literature to date has been to evaluate treatment feasibility, tumor response, disease-free survival, and overall survival in healthy patients. Conventional XELOX and FOLFOX chemotherapy were the most commonly administered interventions. Rationale for selecting a specific regimen and for treatment eligibility criteria were poorly documented across studies. The current literature on neoadjuvant strategies for T4 colon cancer is overrepresented by single-center, retrospective studies that evaluate treatment feasibility and efficacy in healthy patients. Future studies should prioritize evaluating clear selection criteria and rationale for specific neoadjuvant strategies. Validation of outcomes in multi-center, randomized trials for XELOX and FOLFOX have the most to contribute to the growing evidence for this poorly managed disease.Keywords
This publication has 51 references indexed in Scilit:
- Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trialThe Lancet Oncology, 2012
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Revised TN Categorization for Colon Cancer Based on National Survival Outcomes DataJournal of Clinical Oncology, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trialThe Lancet, 2009
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKKAnnals of Oncology, 2008
- Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trialsBritish Journal of Cancer, 2007
- Tumour seeding in peritoneal wound sites in relation to growth-factor expression in early granulation tissueEuropean Journal of Cancer, 2004